Sanofi offers refunds for Cablivi in novel model for rebates
Pharmaceutical Technology
JANUARY 27, 2023
On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. A refund up to 12 inpatient doses will also be offered for patients whose disease worsens while receiving treatment.
52 
Let's personalize your content